02/17/2012 An international team of researchers led by OCRF grantee Anil Sood, MD has found that elevated platelet levels in ovarian cancer patients fuel tumor growth and reduce survival. These findings reveal … Continued
02/16/2012 Work funded by Ovarian Cancer Research Fund has shown that the high-grade serous ovarian cancer arises in the fallopian tube of mice that lack two specific genes. The … Continued
01/27/2012 A large, multicenter study shows that women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes have better survival rates than women who do not … Continued
01/24/2012 The use of symptom indices to identify patients with symptoms associated with ovarian cancer who may need further screening is increasing in both the UK and the US in … Continued
01/20/2012 Dr. Doug Levine and Dr. Carol Aghajanian, both recipients of OCRF grants, were part of a project recently published in Cancer Discovery that studied AKT inhibition in ovarian cancer … Continued
OCRF has awarded $5.4 million in grants for ovarian cancer research this year. After receiving over 100 applications – the highest number in its history – OCRF and its prestigious … Continued
OCRF receives record number of grant applications; continues to fund the best science New York, NY January 3, 2012— Ovarian Cancer Research Fund (OCRF) has awarded $5.4 million in grants … Continued
08/17/2011Researchers in the United Kingdom have discovered a new genetic mutation that increases the risk for ovarian cancer. This major finding was published online in the journal Nature Genetics on … Continued
In a paper published on June 30, 2011 in the journal Nature, researchers working as part of The Cancer Genome Atlas (TCGA) Research Network report that they have created a … Continued
Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Most survivors of gynecologic cancers have menopausal symptoms, and at least one in four takes replacement hormones, results of the first study of its kind showed.
Get email updates about research news, action alerts, and ways to join the fight.
